Hormonal and cardiovascular response to low-intensity exercise with atropine administration.
The hormonal and cardiovascular responses to atropine and low-intensity exercise were examined in 7 young men. Subjects completed 3 trials in a single blind crossover design. During the first trial (T1), subjects received 2.0 mg of atropine intramuscularly at rest. Subsequently in trial 2 (T2), subjects received a saline placebo before 90 minutes of intermittent exercise, and during trial 3 (T3), they received atropine before 90 min of intermittent exercise [3 x (25-minute cycle/5-minute rest) @ 40% VO2 peak]. Venous blood samples and physiological data were collected before, during, and post exercise. Growth hormone (GH) was significantly increased in T2 but unchanged in T1 and T3. Cortisol (CORT) was unchanged in T1 and T2, but in T3 significantly increased (p <0.05) from 45 to 90 minutes compared to T2. Plasma luteinizing hormone (LH) was unaffected in all trials. Plasma prolactin (PRO) significantly increased in T3 from 45 to 90 minutes in comparison to T2. Norepinephrine (NE) was unaffected in T1, but significantly increased in both T2 and T3 (5 to 90 minutes). NE in T3 was also significantly higher compared to T2 (30 to 90 minutes). The heart rate (HR) and rate pressure product (RPP) significantly increased in all trials (15 to 90 minutes) and T3 was significantly elevated in comparison to T2. The administration of atropine before 90 minutes of low-intensity exercise significantly increased cortisol, prolactin, and norepinephrine, decreased growth hormone, and significantly increased cardiovascular stress.
Kamimori
G H
GH
Department of Behavioral Biology, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA.
Bellar
D
D
Fein
H G
HG
Smallridge
R C
RC
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001285:Atropine / Q000494:pharmacology / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000187:drug effects*; D002395:Catecholamines / Q000097:blood; D018592:Cross-Over Studies; D015444:Exercise / Q000502:physiology*; D017079:Exercise Tolerance / Q000187:drug effects; D013006:Growth Hormone / Q000097:blood / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006728:Hormones / Q000097:blood*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood / Q000187:drug effects; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects; D011388:Prolactin / Q000097:blood / Q000187:drug effects; D016037:Single-Blind Method; D014481:United States
D000889:Anti-Arrhythmia Agents; D002395:Catecholamines; D006728:Hormones; D001285:Atropine; D011388:Prolactin; D007986:Luteinizing Hormone; D013006:Growth Hormone; D006854:Hydrocortisone; D009638:Norepinephrine